Indivumed, GmbH and Regeneron Pharmaceuticals Inc. signed an agreement providing Regeneron with access to Indivumed’s quality tissue sample and clinical and molecular data collection methods, to support the company’s cancer research programs.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
